USA At the American trade association’s latest CEO & Investor Conference, the board chair of the Biotechnology Innovation Organization (BIO) Ted W. Love discussed US policies and speculated about the impact of the upcoming American election on the industry while affirming that biotech continues to thrive in spite of recent challenges.…
India Dr Viranchi Shah of Saga Lifesciences and the Indian Drug Manufacturers Association (IDMA) outlines the Indian pharmaceutical industry’s potential for growth and its role in global health initiatives. He highlights IDMA’s focus on scaling operations, affordability, accessibility, quality, and compliance to drive positive change across the sector. Dr Shah also…
India J&J India’s Jayashri Kulkarni lays out her approach to comprehensive leadership, drawing on her diverse career history across various sectors; her mandate to leverage innovative assets to transform disease management in India; and the importance of actively championing diversity, equity, and inclusion (DEI) within the company, building a future-fit organization…
India Dr Arunish Chawla details the policy strategies underlying the explosive prospected growth of India’s pharmaceutical sector to USD 120-150 billion by 2030, including rigorous adherence to international quality standards. Highlighting regulatory reforms and India’s nuanced stance on intellectual property, Dr Chawla envisions India as a balanced player in healthcare across…
India At a transformational moment for Indian pharma, OPPI’s Anil Matai outlines how the country’s government is more receptive to innovation and action-oriented than ever before, how the industry is increasingly aligning with global standards to foster an innovation transition, and the importance of always bearing patiennt accessibility in mind in…
Portugal Joana Branco of Biocant Park, Portugal’s pioneering biotech hub, delves into its strategic development and international impact since 2005. Branco highlights Biocant’s role in advancing the Portuguese life sciences sector, attracting around 43 companies with its state-of-the-art infrastructure and a collaborative ecosystem. Despite challenges such as Portugal’s size and the…
Portugal Pfizer holds a prominent position in Portugal’s pharmaceutical landscape, especially in the hospital business and for COVID-19-related products, with the emphasis now on sustainable growth post-COVID. Paulo Teixeira, a 26-year pharma industry veteran, lays out his strategy for the affiliate and highlights some of the key challenges in Portugal’s healthcare…
Portugal Health Cluster Portugal is currently spearheading a EUR 90 million EU post-COVID Recovery and Resilience Plan (RRP) project in Portugal focused on smart health, secondary use of data, and clinical trials. Executive Director Joaquim Cunha highlights the ways in which COVID acted as a catalyst for healthcare transformation more broadly,…
Portugal Portugal boasts a well-developed universal healthcare system and saw healthcare spending increase by 6.2 percent annually between 2016 and 2021, according to the OECD. However, the representatives of innovative medicines manufacturers embedded in the country are keen to point out that access to the latest drugs remains a big issue…
Portugal Speaking to PharmaBoardroom as Janseen is rebranding as Johnson & Johnson Innovative Medicine, managing director for Portugal, Filipa Mota e Costa, discusses the affiliate’s expanded local footprint and its ranking as the number one pharmaceutical company in the country. She also explains Portugal’s market access progress, including the consolidation of…
India Pratima Reddy, GM at Merck Healthcare India reviews the importance of Merck’s Indian affiliate, discusses the recent reforms that have contributed both to improving patient access and to fostering foreign investments and innovation, and explains the representation of Merck’s portfolio in the country, and how the company navigates the local…
Brazil The latest pharma news from Brazil, including the partnership between Biophytis and Innovation Solutions Pharma; Merck’s 100 years in Brazil; Eurofarma’s USD 100 million biotech investment, and GSK’s green light from ANVISA. Biophytis and Innovation Solutions Pharma Sign a Partnership Agreement to Accelerate Market Access for Sarconeos in Brazil…
See our Cookie Privacy Policy Here
